Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Holdings Lessened by Jane Street Group LLC

Jane Street Group LLC decreased its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 85.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,168 shares of the company's stock after selling 103,013 shares during the quarter. Jane Street Group LLC's holdings in Myriad Genetics were worth $249,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Myriad Genetics by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 10,591,043 shares of the company's stock valued at $145,203,000 after acquiring an additional 279,379 shares in the last quarter. Earnest Partners LLC increased its holdings in shares of Myriad Genetics by 0.4% during the fourth quarter. Earnest Partners LLC now owns 3,971,598 shares of the company's stock valued at $54,451,000 after purchasing an additional 15,650 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of Myriad Genetics by 13.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,766,729 shares of the company's stock valued at $37,932,000 after purchasing an additional 336,770 shares in the last quarter. Sei Investments Co. lifted its holdings in Myriad Genetics by 7.4% in the fourth quarter. Sei Investments Co. now owns 2,526,761 shares of the company's stock worth $34,642,000 after purchasing an additional 174,770 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Myriad Genetics by 3.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,125,535 shares of the company's stock worth $15,431,000 after purchasing an additional 42,233 shares during the period. Institutional investors own 99.02% of the company's stock.

Analyst Ratings Changes

MYGN has been the topic of a number of recent analyst reports. Raymond James restated an "outperform" rating and set a $10.00 price target (down from $19.00) on shares of Myriad Genetics in a research report on Wednesday, May 7th. The Goldman Sachs Group dropped their target price on Myriad Genetics from $14.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Craig Hallum set a $18.00 target price on Myriad Genetics and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Piper Sandler decreased their price target on Myriad Genetics from $12.50 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Finally, Scotiabank downgraded Myriad Genetics from a "sector outperform" rating to a "sector perform" rating and dropped their price objective for the stock from $20.00 to $6.00 in a research note on Wednesday, May 21st. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $14.38.

Myriad Genetics Trading Up 3.5%

MYGN traded up $0.17 during trading on Friday, reaching $5.09. The company had a trading volume of 1,685,827 shares, compared to its average volume of 1,210,340. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics, Inc. has a 12-month low of $3.81 and a 12-month high of $29.30. The company has a market cap of $469.18 million, a price-to-earnings ratio of -3.92 and a beta of 1.84. The firm's 50-day simple moving average is $6.24 and its 200 day simple moving average is $10.67.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The business had revenue of $195.90 million for the quarter, compared to the consensus estimate of $200.37 million. During the same period last year, the firm posted ($0.01) earnings per share. The firm's quarterly revenue was down 33.6% compared to the same quarter last year. Equities research analysts anticipate that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.